-
Product Insights
NewMycosis Fungoides Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Mycosis Fungoides Clinical Trial Report Overview A total of 328 mycosis fungoides clinical trials were conducted as of April 2024. The mycosis fungoides clinical trial report provides a comprehensive understanding of the mycosis fungoides clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       North America ·       ...
-
Innovation Ranking
NewInnovation Ranking – Soligenix Inc
Soligenix Inc (Soligenix) is a late-stage biopharmaceutical company which focuses on the development and commercialization of products for the treatment of rare diseases and unmet medical needs. It develops specialized biotherapeutics for the treatment of orphan diseases such as cutaneous T-cell lymphoma, pediatric Crohn's disease, oral mucositis, mild to moderate psoriasis and acute radiation enteritis. It develops proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the treatment of gastrointestinal disorders that are characterized by high inflammation. The company has active...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Beclomethasone Dipropionate in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Beclomethasone Dipropionate in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Beclomethasone Dipropionate in Crohn's Disease (Regional Enteritis) Drug Details:...
-
Product Insights
Cutaneous T-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Cutaneous T-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Cutaneous T-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cutaneous T-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Marburgvirus Infections (Marburg Hemorrhagic Fever) – Drugs In Development, 2023
Global Markets Direct’s, ‘Marburgvirus Infections (Marburg Hemorrhagic Fever) - Drugs In Development, 2023’, provides an overview of the Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Mycosis Fungoides – Drugs In Development, 2023
Global Markets Direct’s, ‘Mycosis Fungoides - Drugs In Development, 2023’, provides an overview of the Mycosis Fungoides pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mycosis Fungoides, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Burkholderia Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Burkholderia Infections - Drugs In Development, 2023’, provides an overview of the Burkholderia Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Burkholderia Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2023
Global Markets Direct’s, ‘Plaque Psoriasis (Psoriasis Vulgaris) - Drugs In Development, 2023’, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Ebolavirus Infections (Ebola Hemorrhagic Fever) – Drugs In Development, 2023
Global Markets Direct’s, ‘Ebolavirus Infections (Ebola Hemorrhagic Fever) - Drugs In Development, 2023’, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BAY-2965501 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BAY-2965501 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BAY-2965501 in Solid Tumor Drug Details: BAY-2965501 is under development for...